16
Participants
Start Date
July 25, 2018
Primary Completion Date
February 1, 2021
Study Completion Date
February 1, 2021
Rogaratinib (BAY1163877)
"Dose escalation:~Starting dose is rogaratinib 400 mg twice daily (b.i.d.) in continuous 28-day cycles from Cycle 1 Day 3 onwards.~Dose expansion:~With dose identified in dose escalation part."
Copanlisib (BAY80-6946)
"Dose escalation:~Starting dose is 45 mg on Days 1, 8 and 15 of each 28-day cycle.~Dose expansion:~With dose identified in dose escalation part."
CU Saint-Luc/UZ St-Luc, Bruxelles - Brussel
UZ Antwerpen, Edegem
CHU de Liège, Liège
Memorial Sloan-Kettering Cancer Center, New York
University of Maryland, Baltimore
Hospital Clínico Universitario de Valencia, Valencia
Barbara Ann Karmanos Cancer Institute - Detroit, Detroit
Universitätsklinikum Köln, Cologne
Krankenhaus Nordwest, Frankfurt am Main
Northwestern University, Chicago
Tyler Cancer Center, Tyler
USC Norris Hospital and Clinics, Los Angeles
Klinikum der Universität Würzburg, Würzburg
National University Hospital, Singapore
National Cancer Center Singapore, Singapore
Dana-Farber Cancer Institute, Boston
Severance Hospital, Yonsei University Health System, Seoul
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Ciutat Sanitària i Universitaria de la Vall d'Hebron, Barcelona
Lead Sponsor
Bayer
INDUSTRY